503184-35-8

Usage

Uses

Used in Pharmaceutical Industry:
2-Methoxy-4-methyl-pyridine-5-boronic acid is used as a reagent for the synthesis of various pharmaceutical compounds due to its ability to form carbon-carbon and carbon-heteroatom bonds. Its participation in Suzuki-Miyaura cross-coupling reactions allows for the creation of diverse molecular structures, contributing to the development of new drugs with improved efficacy and safety profiles.
Used in Agrochemical Industry:
In the agrochemical industry, 2-methoxy-4-methyl-pyridine-5-boronic acid serves as a key intermediate in the synthesis of agrochemicals, such as pesticides and herbicides. Its versatility in forming different types of chemical bonds enables the production of a wide range of active ingredients with targeted pest control properties.
Used in Materials Science:
2-Methoxy-4-methyl-pyridine-5-boronic acid is utilized as a building block in the development of advanced materials with specific properties. Its ability to form carbon-carbon and carbon-heteroatom bonds allows for the creation of materials with tailored characteristics, such as improved mechanical strength, thermal stability, or electrical conductivity.
Used in Organic Synthesis:
As a versatile reagent in organic synthesis, 2-methoxy-4-methyl-pyridine-5-boronic acid is used for the formation of complex organic compounds. Its boronic acid group facilitates Suzuki-Miyaura cross-coupling reactions, enabling the synthesis of a broad range of organic molecules with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Biological and Pharmacological Research:
The presence of the pyridine ring in 2-methoxy-4-methyl-pyridine-5-boronic acid provides the compound with potential biological activity, making it a candidate for research in biological and pharmacological applications. Its unique structure may offer opportunities for the development of new therapeutic agents or probes for studying biological processes.

InChI:InChI=1/C7H10BNO3/c1-5-3-7(12-2)9-4-6(5)8(10)11/h3-4,10-11H,1-2H3

Upstream product

• 164513-39-7 5-bromo-2-methoxy-4-methylpyridine 

Downstream Products

• 1612287-86-1 5-(6-methoxy-4-methylpyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-c]pyridine 
• 1612288-03-5 2-(2-chloro-6-fluorophenyl)-5-(6-methoxy-4-methylpyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1580504-38-6 2-(4-(6-methoxy-4-methylpyridin-3-yl)benzyloxy)nicotinamide 
• 1380106-61-5 3-[2-chloro-4-(6-methoxy-4-methyl-pyridin-3-yl)-phenyl]-N-hydroxy-acrylamide hydrochloride 
• 503184-29-0 2'-benzyloxy-6-methoxy-4-methyl-3'-nitro-[3,4']bipyridinyl 

Relevant academic research and scientific papers

New bicyclic compounds as crac channel modulators

The present invention relates to novel compounds which are inhibitors of CRAC channel activity. This invention also relates to pharmaceutical compositions containing them, process for their preparation and their use in therapy.

Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1, 5-a]-1,3,5-triazines: Potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists

This report describes the syntheses and structure-activity relationships of 8-(substituted pyridyl)pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF1) receptor antagonists. These CRF1 receptor antagonists may be potential anxiolytic or antidepressant drugs. This research resulted in the discovery of compound 13-15, which is a potent, selective CRF1 antagonist (hCRF1 IC50 = 6.1 ± 0.6 nM) with weak affinity for the CRF-binding protein and biogenic amine receptors. This compound also has a good pharmacokinetic profile in dogs. Analogue 13-15 is orally effective in two rat models of anxiety: the defensive withdrawal (situational anxiety) model and the elevated plus maze test. Analogue 13-15 has been advanced to clinical trials.

New FBPase inhibitors for diabetes

Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R3 have the significance given in the application and which can be used in the form of pharmaceutical compositions.

CRF ligands via Suzuki and Negishi couplings of 3-pyridyl boronic acids or halides with 2-benzyloxy-4-chloro-3-nitropyridine.

A series of imidazo[4,5-b]pyridines with a 7-(3-pyridyl) substituent is described as high affinity CRF receptor ligands. Individual analogues were synthesized from key intermediates obtained via palladium-catalyzed coupling of 3-pyridyl zinc or boronic acid organometallic intermediates with 2-benzyloxy-4-chloro-3-nitropyridine 12.